About Thymidine kinase, cytosolic
Thymidine kinase, cytosolic (TK1) is a protein
from Homo sapiens identified by UniProt accession
P04183, 234 residues long.
MolForge cross-references it against 0 known binders and
220 disease associations.
Target properties
| Protein name | Thymidine kinase, cytosolic |
|---|
| UniProt accession | P04183 |
|---|
| Gene | TK1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 234 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (220)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.37
- mean corpuscular volume · score 0.37
- mean corpuscular hemoglobin · score 0.28
- mean corpuscular hemoglobin concentration · score 0.27
- neurodegenerative disease · score 0.27
- mean reticulocyte volume · score 0.27
- erythrocyte count · score 0.26
- red blood cell density measurement · score 0.22
- reticulocyte count · score 0.18
- telomere length · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04183-F1 | alphafold | PREDICTED | 82.12 | — |
Amino-acid sequence (234 residues)
MSCINLPTVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC LVIKYAKDTR YSSSFCTHDR NTMEALPACL LRDVAQEALG VAVIGIDEGQ FFPDIVEFCE AMANAGKTVI VAALDGTFQR KPFGAILNLV PLAESVVKLT AVCMECFREA AYTKRLGTEK EVEVIGGADK YHSVCRLCYF KKASGQPAGP DNKENCPVPG KPGEAVAARK LFAPQQILQC SPAN
Explore Thymidine kinase, cytosolic with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets